ECSP23096182A - Inhibidores de alk2 quinasa que contienen imidazol - Google Patents
Inhibidores de alk2 quinasa que contienen imidazolInfo
- Publication number
- ECSP23096182A ECSP23096182A ECSENADI202396182A ECDI202396182A ECSP23096182A EC SP23096182 A ECSP23096182 A EC SP23096182A EC SENADI202396182 A ECSENADI202396182 A EC SENADI202396182A EC DI202396182 A ECDI202396182 A EC DI202396182A EC SP23096182 A ECSP23096182 A EC SP23096182A
- Authority
- EC
- Ecuador
- Prior art keywords
- kinase inhibitors
- compounds
- pharmaceutically acceptable
- inhibitors containing
- containing imidazole
- Prior art date
Links
- 102100034111 Activin receptor type-1 Human genes 0.000 title abstract 2
- 101000799140 Homo sapiens Activin receptor type-1 Proteins 0.000 title abstract 2
- 229940043355 kinase inhibitor Drugs 0.000 title abstract 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 title abstract 2
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 title 2
- RAXXELZNTBOGNW-UHFFFAOYSA-O Imidazolium Chemical compound C1=C[NH+]=CN1 RAXXELZNTBOGNW-UHFFFAOYSA-O 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 3
- 206010068715 Fibrodysplasia ossificans progressiva Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se divulgan compuestos de la Fórmula I, II, III y IV, y sales aceptables desde el punto de vista farmacéutico de estos. Los compuestos son inhibidores de ALK2 quinasa. Además, se proporcionan composiciones farmacéuticas que comprenden un compuesto de la Fórmula I, II, III o IV, o una sal aceptable desde el punto de vista farmacéutico de este, y métodos que implican el uso de los compuestos o las sales aceptables desde el punto de vista farmacéutico de estos y las composiciones en el tratamiento y la prevención de diversas enfermedades y afecciones, tales como fibrodisplasia osificante progresiva.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163192822P | 2021-05-25 | 2021-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP23096182A true ECSP23096182A (es) | 2024-01-31 |
Family
ID=84230377
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECSENADI202396182A ECSP23096182A (es) | 2021-05-25 | 2023-12-22 | Inhibidores de alk2 quinasa que contienen imidazol |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20240270750A1 (es) |
| EP (1) | EP4346806A2 (es) |
| JP (1) | JP2024520359A (es) |
| KR (1) | KR20240013145A (es) |
| CN (1) | CN117529315A (es) |
| AR (1) | AR125963A1 (es) |
| AU (1) | AU2022283258A1 (es) |
| BR (1) | BR112023024537A2 (es) |
| CA (1) | CA3219966A1 (es) |
| CL (1) | CL2023003503A1 (es) |
| CO (1) | CO2023017975A2 (es) |
| CR (1) | CR20230597A (es) |
| DO (1) | DOP2023000254A (es) |
| EC (1) | ECSP23096182A (es) |
| IL (1) | IL308513A (es) |
| MX (1) | MX2023013742A (es) |
| TW (1) | TW202313625A (es) |
| UY (1) | UY39788A (es) |
| WO (1) | WO2022251188A2 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070244114A1 (en) * | 2004-07-06 | 2007-10-18 | Myriad Genetics, Incorporated | Compounds and therapeutical use thereof |
| MX2011003447A (es) * | 2008-09-30 | 2011-07-29 | Astrazeneca Ab | Inhibidores heterociclicos de jak quinasa. |
| AR112027A1 (es) * | 2017-06-15 | 2019-09-11 | Biocryst Pharm Inc | Inhibidores de alk 2 quinasa que contienen imidazol |
-
2022
- 2022-05-24 CA CA3219966A patent/CA3219966A1/en active Pending
- 2022-05-24 EP EP22811963.2A patent/EP4346806A2/en active Pending
- 2022-05-24 JP JP2023571902A patent/JP2024520359A/ja active Pending
- 2022-05-24 UY UY0001039788A patent/UY39788A/es unknown
- 2022-05-24 IL IL308513A patent/IL308513A/en unknown
- 2022-05-24 US US18/562,115 patent/US20240270750A1/en active Pending
- 2022-05-24 CR CR20230597A patent/CR20230597A/es unknown
- 2022-05-24 WO PCT/US2022/030690 patent/WO2022251188A2/en active Application Filing
- 2022-05-24 CN CN202280037483.5A patent/CN117529315A/zh active Pending
- 2022-05-24 AR ARP220101377A patent/AR125963A1/es unknown
- 2022-05-24 KR KR1020237042819A patent/KR20240013145A/ko unknown
- 2022-05-24 MX MX2023013742A patent/MX2023013742A/es unknown
- 2022-05-24 BR BR112023024537A patent/BR112023024537A2/pt unknown
- 2022-05-24 AU AU2022283258A patent/AU2022283258A1/en active Pending
- 2022-05-25 TW TW111119373A patent/TW202313625A/zh unknown
-
2023
- 2023-11-16 DO DO2023000254A patent/DOP2023000254A/es unknown
- 2023-11-24 CL CL2023003503A patent/CL2023003503A1/es unknown
- 2023-12-20 CO CONC2023/0017975A patent/CO2023017975A2/es unknown
- 2023-12-22 EC ECSENADI202396182A patent/ECSP23096182A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202313625A (zh) | 2023-04-01 |
| CR20230597A (es) | 2024-02-20 |
| IL308513A (en) | 2024-01-01 |
| DOP2023000254A (es) | 2023-12-29 |
| CN117529315A (zh) | 2024-02-06 |
| UY39788A (es) | 2023-01-31 |
| CO2023017975A2 (es) | 2024-01-15 |
| EP4346806A2 (en) | 2024-04-10 |
| WO2022251188A2 (en) | 2022-12-01 |
| JP2024520359A (ja) | 2024-05-24 |
| CL2023003503A1 (es) | 2024-05-03 |
| CA3219966A1 (en) | 2022-12-01 |
| AU2022283258A1 (en) | 2024-01-04 |
| WO2022251188A3 (en) | 2023-01-05 |
| WO2022251188A8 (en) | 2024-01-04 |
| MX2023013742A (es) | 2023-11-28 |
| AR125963A1 (es) | 2023-08-30 |
| BR112023024537A2 (pt) | 2024-02-06 |
| KR20240013145A (ko) | 2024-01-30 |
| US20240270750A1 (en) | 2024-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020000194A2 (es) | Inhibidores de quinasa alk2 que contienen imidazol | |
| CO2022001357A2 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| AR116604A1 (es) | Inhibidores de kras g12c | |
| CO2022008091A2 (es) | Inhibidores de kras g12c | |
| UY37133A (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| AR122351A1 (es) | Derivados de metilquinazolinona como inhibidores de braf | |
| AR067599A1 (es) | Derivados de indazol sustituido activos como inhibidores de quinasa | |
| AR103828A1 (es) | INHIBIDORES DEL FACTOR TRANSFORMADOR DEL CRECIMIENTO b | |
| PH12020552244A1 (en) | Heterocyclic compounds as trk inhibitors | |
| DOP2012000053A (es) | Derivados de (tio) morfolina como moduladores de s1p | |
| AR119206A1 (es) | DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR | |
| PE20181017A1 (es) | Compuestos heteroarilo y su uso como farmacos terapeuticos | |
| UY37331A (es) | Derivados de aminopiridina y su uso como inhibidores selectivos de alk-2 | |
| ECSP23096182A (es) | Inhibidores de alk2 quinasa que contienen imidazol | |
| CO2021017202A2 (es) | Compuestos tricíclicos | |
| CL2023001277A1 (es) | Derivados de pirazol como inhibidores de la ret-cinasa | |
| PE20211454A1 (es) | Derivados de imidazopiridina y su uso como medicamento | |
| UY39308A (es) | Derivados de aminopirimidinilo | |
| CO2024011088A2 (es) | Macrociclos de imidazol para el tratamiento de enfermedades autoinmunitarias | |
| ECSP23075535A (es) | Compuestos cíclicos y métodos de uso | |
| AR128879A1 (es) | DERIVADOS DE PIRIDO-[3,4-d]PIRIDAZINA AMINA ÚTILES COMO DERIVADOS DE NLRP3 | |
| AR120154A1 (es) | Inhibidor de diacilglicerol aciltransferasa 2 | |
| AR120835A1 (es) | Compuestos químicos | |
| AR120800A1 (es) | Derivados de 6,7-dihidro-5h-pirrolo[1,2-c]imidazol como inhibidores de egfr |